Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab.
- Binet, Quentin
- Hammer, Frank
- Rocrelle, Olivia
- Peeters, André
- Scavée, Christophe
- Hermans, Cédric
DOIAbstract
Patients presenting with an acute ischemic stroke despite dabigatran therapy (last intake <24 h or unknown) should be evaluated for reversal by idarucizumab, making them eligible for safe and effective intravenous thrombolysis. It has been shown to be feasible, well-tolerated, and easy to manage in an emergency room or stroke unit
Add to ORKG